APO RESEARCH · REPORT
Medical Hemostatic Agents
Mechanical agents (also called passive substances) are generally thought to be the most effective for small amounts of bleeding and they create a barrier to stop blood flow and a surface that permits blood to clot more rapidly.
Product & engineering
Understand the product.
Mechanical agents (also called passive substances) are generally thought to be the most effective for small amounts of bleeding and they create a barrier to stop blood flow and a surface that permits blood to clot more rapidly.
Selected research
Industry Research
Medical Hemostatic Agents Industry Research Report 2026
Market perspective
Mechanical agents (also called passive substances) are generally thought to be the most effective for small amounts of bleeding and they create a barrier to stop blood flow and a surface that permits blood to clot more rapidly.
North America is the largest consumption region, with a more than 40% market share. Then Europe is the second largest consumption region with the market share of about 30%. J&J, Baxter, BD, Gelita, Pfizer, B Braun are the leaders of the global Medical Hemostatic Agents market, and they hold more than 65% market share. Medical Hemostatic Agents is widely used in Hospital, Surgical Centers and other field. The most proportion of Medical Hemostatic Agents is Hospital, and the sales proportion is about 65%. The classification of Medical Hemostatic Agents includes Gelation Hemostats, Combination Hemostats and Others Type. The proportion of Combination Hemostats and Gelation Hemostats in 2019 is more than 50%.
Report Scope
Read the full market overview
This report quantifies the global Medical Hemostatic Agents market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Medical Hemostatic Agents Market by Company
J&J
Baxter
BD
Gelita
Pfizer
B Braun
CSL Behring
Ferrosan Medical Devices
Advance Medical Solution
Medtronic
Z-Medica
Marine Polymer
Equimedical
CryoLife
Medical Hemostatic Agents Segment by Type
Gelation Hemostats
Combination Hemostats
Others
Medical Hemostatic Agents Segment by Application
Hospitals
Surgical Centers
Others
Medical Hemostatic Agents Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Medical Hemostatic Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Medical Hemostatic Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Medical Hemostatic Agents.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Medical Hemostatic Agents manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Medical Hemostatic Agents by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Medical Hemostatic Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Gelation Hemostats
- Combination Hemostats
- Others
Applications
- Hospitals
- Surgical Centers
- Others
Companies covered
- J&J
- Baxter
- BD
- Gelita
- Pfizer
- B Braun
- CSL Behring
- Ferrosan Medical Devices
- Advance Medical Solution
- Medtronic
- Z-Medica
- Marine Polymer
- Equimedical
- CryoLife
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Medical Hemostatic Agents Market Size (2021-2032)
- 2.2.2 Global Medical Hemostatic Agents Sales (2021-2032)
- 2.2.3 Global Medical Hemostatic Agents Market Average Price (2021-2032)
- 2.3 Medical Hemostatic Agents by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Gelation Hemostats
- 2.3.3 Combination Hemostats
- 2.3.4 Others
- 2.4 Medical Hemostatic Agents by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Surgical Centers
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Medical Hemostatic Agents Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Medical Hemostatic Agents Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Medical Hemostatic Agents Revenue of Manufacturers (2021-2026)
- 3.4 Global Medical Hemostatic Agents Average Price by Manufacturers (2021-2026)
- 3.5 Global Medical Hemostatic Agents Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Medical Hemostatic Agents, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Medical Hemostatic Agents, Product Type & Application
- 3.8 Global Manufacturers of Medical Hemostatic Agents, Established Date
- 3.9 Global Medical Hemostatic Agents Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 J&J
- 4.1.1 J&J Company Information
- 4.1.2 J&J Business Overview
- 4.1.3 J&J Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 J&J Medical Hemostatic Agents Product Portfolio
- 4.1.5 J&J Recent Developments
- 4.2 Baxter
- 4.2.1 Baxter Company Information
- 4.2.2 Baxter Business Overview
- 4.2.3 Baxter Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Baxter Medical Hemostatic Agents Product Portfolio
- 4.2.5 Baxter Recent Developments
- 4.3 BD
- 4.3.1 BD Company Information
- 4.3.2 BD Business Overview
- 4.3.3 BD Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 BD Medical Hemostatic Agents Product Portfolio
- 4.3.5 BD Recent Developments
- 4.4 Gelita
- 4.4.1 Gelita Company Information
- 4.4.2 Gelita Business Overview
- 4.4.3 Gelita Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Gelita Medical Hemostatic Agents Product Portfolio
- 4.4.5 Gelita Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Medical Hemostatic Agents Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 B Braun
- 4.6.1 B Braun Company Information
- 4.6.2 B Braun Business Overview
- 4.6.3 B Braun Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 B Braun Medical Hemostatic Agents Product Portfolio
- 4.6.5 B Braun Recent Developments
- 4.7 CSL Behring
- 4.7.1 CSL Behring Company Information
- 4.7.2 CSL Behring Business Overview
- 4.7.3 CSL Behring Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 CSL Behring Medical Hemostatic Agents Product Portfolio
- 4.7.5 CSL Behring Recent Developments
- 4.8 Ferrosan Medical Devices
- 4.8.1 Ferrosan Medical Devices Company Information
- 4.8.2 Ferrosan Medical Devices Business Overview
- 4.8.3 Ferrosan Medical Devices Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Ferrosan Medical Devices Medical Hemostatic Agents Product Portfolio
- 4.8.5 Ferrosan Medical Devices Recent Developments
- 4.9 Advance Medical Solution
- 4.9.1 Advance Medical Solution Company Information
- 4.9.2 Advance Medical Solution Business Overview
- 4.9.3 Advance Medical Solution Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Advance Medical Solution Medical Hemostatic Agents Product Portfolio
- 4.9.5 Advance Medical Solution Recent Developments
- 4.10 Medtronic
- 4.10.1 Medtronic Company Information
- 4.10.2 Medtronic Business Overview
- 4.10.3 Medtronic Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Medtronic Medical Hemostatic Agents Product Portfolio
- 4.10.5 Medtronic Recent Developments
- 4.11 Z-Medica
- 4.11.1 Z-Medica Company Information
- 4.11.2 Z-Medica Business Overview
- 4.11.3 Z-Medica Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Z-Medica Medical Hemostatic Agents Product Portfolio
- 4.11.5 Z-Medica Recent Developments
- 4.12 Marine Polymer
- 4.12.1 Marine Polymer Company Information
- 4.12.2 Marine Polymer Business Overview
- 4.12.3 Marine Polymer Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Marine Polymer Medical Hemostatic Agents Product Portfolio
- 4.12.5 Marine Polymer Recent Developments
- 4.13 Equimedical
- 4.13.1 Equimedical Company Information
- 4.13.2 Equimedical Business Overview
- 4.13.3 Equimedical Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Equimedical Medical Hemostatic Agents Product Portfolio
- 4.13.5 Equimedical Recent Developments
- 4.14 CryoLife
- 4.14.1 CryoLife Company Information
- 4.14.2 CryoLife Business Overview
- 4.14.3 CryoLife Medical Hemostatic Agents Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 CryoLife Medical Hemostatic Agents Product Portfolio
- 4.14.5 CryoLife Recent Developments
5 Global Medical Hemostatic Agents Market Scenario by Region
- 5.1 Global Medical Hemostatic Agents Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Medical Hemostatic Agents Sales by Region: 2021-2032
- 5.2.1 Global Medical Hemostatic Agents Sales by Region: 2021-2026
- 5.2.2 Global Medical Hemostatic Agents Sales by Region: 2027-2032
- 5.3 Global Medical Hemostatic Agents Revenue by Region: 2021-2032
- 5.3.1 Global Medical Hemostatic Agents Revenue by Region: 2021-2026
- 5.3.2 Global Medical Hemostatic Agents Revenue by Region: 2027-2032
- 5.4 North America Medical Hemostatic Agents Market Facts & Figures by Country
- 5.4.1 North America Medical Hemostatic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Medical Hemostatic Agents Sales by Country (2021-2032)
- 5.4.3 North America Medical Hemostatic Agents Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Medical Hemostatic Agents Market Facts & Figures by Country
- 5.5.1 Europe Medical Hemostatic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Medical Hemostatic Agents Sales by Country (2021-2032)
- 5.5.3 Europe Medical Hemostatic Agents Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Medical Hemostatic Agents Market Facts & Figures by Country
- 5.6.1 Asia Pacific Medical Hemostatic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Medical Hemostatic Agents Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Medical Hemostatic Agents Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Medical Hemostatic Agents Market Facts & Figures by Country
- 5.7.1 South America Medical Hemostatic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Medical Hemostatic Agents Sales by Country (2021-2032)
- 5.7.3 South America Medical Hemostatic Agents Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Medical Hemostatic Agents Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Medical Hemostatic Agents Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Medical Hemostatic Agents Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Medical Hemostatic Agents Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Medical Hemostatic Agents Sales by Type (2021-2032)
- 6.1.1 Global Medical Hemostatic Agents Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Medical Hemostatic Agents Sales Market Share by Type (2021-2032)
- 6.2 Global Medical Hemostatic Agents Revenue by Type (2021-2032)
- 6.2.1 Global Medical Hemostatic Agents Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Medical Hemostatic Agents Revenue Market Share by Type (2021-2032)
- 6.3 Global Medical Hemostatic Agents Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Medical Hemostatic Agents Sales by Application (2021-2032)
- 7.1.1 Global Medical Hemostatic Agents Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Medical Hemostatic Agents Sales Market Share by Application (2021-2032)
- 7.2 Global Medical Hemostatic Agents Revenue by Application (2021-2032)
- 7.2.1 Global Medical Hemostatic Agents Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Medical Hemostatic Agents Revenue Market Share by Application (2021-2032)
- 7.3 Global Medical Hemostatic Agents Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Medical Hemostatic Agents Value Chain Analysis
- 8.1.1 Medical Hemostatic Agents Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Medical Hemostatic Agents Production Mode & Process
- 8.2 Medical Hemostatic Agents Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Medical Hemostatic Agents Distributors
- 8.2.3 Medical Hemostatic Agents Customers
9 Global Medical Hemostatic Agents Analyzing Market Dynamics
- 9.1 Medical Hemostatic Agents Industry Trends
- 9.2 Medical Hemostatic Agents Industry Drivers
- 9.3 Medical Hemostatic Agents Industry Opportunities and Challenges
- 9.4 Medical Hemostatic Agents Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst